FY2025 Earnings Estimate for Geron Issued By B. Riley

Geron Co. (NASDAQ:GERN) – Equities research analysts at B. Riley decreased their FY2025 EPS estimates for Geron in a research note issued on Wednesday, February 26th. B. Riley analyst K. Patel now anticipates that the biopharmaceutical company will post earnings of ($0.11) per share for the year, down from their previous forecast of ($0.08). B. Riley has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. B. Riley also issued estimates for Geron’s FY2026 earnings at ($0.02) EPS and FY2027 earnings at $0.08 EPS.

A number of other research analysts have also recently commented on the stock. Barclays restated an “overweight” rating and issued a $4.00 price target (down from $9.00) on shares of Geron in a report on Thursday, February 27th. Scotiabank decreased their price objective on shares of Geron from $6.00 to $4.00 and set a “sector outperform” rating for the company in a research report on Thursday, February 27th. HC Wainwright cut shares of Geron from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 26th. Stifel Nicolaus decreased their target price on Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Finally, Needham & Company LLC reduced their price target on Geron from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $5.68.

Geron Trading Down 2.9 %

GERN stock opened at $1.66 on Monday. The firm’s fifty day simple moving average is $2.90 and its two-hundred day simple moving average is $3.75. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $1.00 billion, a price-to-earnings ratio of -5.19 and a beta of 0.53. Geron has a twelve month low of $1.46 and a twelve month high of $5.34.

Geron (NASDAQ:GERN) last announced its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, hitting the consensus estimate of ($0.04). Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The company had revenue of $47.54 million for the quarter, compared to analysts’ expectations of $45.29 million.

Hedge Funds Weigh In On Geron

A number of institutional investors and hedge funds have recently made changes to their positions in GERN. Alternative Investment Advisors LLC. lifted its stake in Geron by 13.3% in the third quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 2,612 shares during the last quarter. Rovin Capital UT ADV grew its holdings in Geron by 26.9% in the fourth quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 3,660 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Geron by 23.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 21,802 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 4,094 shares during the last quarter. Xponance Inc. lifted its position in shares of Geron by 12.9% in the fourth quarter. Xponance Inc. now owns 42,401 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 4,829 shares in the last quarter. Finally, US Bancorp DE lifted its position in shares of Geron by 68.4% in the third quarter. US Bancorp DE now owns 18,296 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 7,429 shares in the last quarter. 73.71% of the stock is owned by institutional investors and hedge funds.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.